Drugs / FMX114
last change Aug 2022 re-read 3 minutes ago

FMX114

Developed for
atopic eczema
Investigated by
Vyne Therapeutics Inc.

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04927572 Oct 2021 → Aug 2022 atopic eczema Vyne Therapeutics Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as FMX114 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04927572 ↗